C7orf31 Inhibitors
C7orf31 inhibitors encompass a range of chemicals that interact with various signaling pathways, ultimately leading to the inhibition of C7orf31 activity. Staurosporine, for instance, is a broad-spectrum kinase inhibitor that disrupts phosphorylation processes critical to C7orf31's function, while LY294002 and Wortmannin target PI3K directly, potentially downregulating AKT signaling that could be essential for C7orf31's post-translational modification or activity. Rapamycin's complex with FKBP12 inhibits mTOR, which is implicated in the synthesis of numerous proteins, possibly including C7orf31, and thus could indirectly reduce its activity. Bortezomib and MG132, both proteasome inhibitors, may lead to an accumulation of proteins that negatively regulate C7orf31's synthesis or function.
Furthermore, PD98059 and U0126, both MEK inhibitors, along with SB203580, a p38 MAPK inhibitor, and SP600125, a JNK inhibitor, all interfere with different aspects of the MAPK pathway. These inhibitors may alter C7orf31's regulation or expression by preventing the necessary phosphorylationevents within the pathway. Dasatinib and Imatinib, as kinase inhibitors, could impede signaling cascades that involve Src family kinases and tyrosine kinases like Abl, respectively, potentially affecting downstream processes that govern the stability or activity of C7orf31. Each inhibitor operates through unique mechanisms but converges on the common outcome of C7orf31 activity inhibition, whether by altering phosphorylation states, modulating protein synthesis, or affecting regulatory protein stability. Their actions reflect a diverse yet interconnected network of cellular signals that, when inhibited, contribute to the decreased activity of C7orf31, highlighting the complexity of intracellular signaling and the multifaceted nature of protein regulation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases. By inhibiting kinase activity, it can disrupt phosphorylation events crucial for the function and regulation of C7orf31, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. PI3K inhibition can downregulate AKT signaling, which may be necessary for the post-translational modification or activity of C7orf31, therefore inhibiting its function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, which is involved in protein synthesis and cell growth. Inhibition of mTOR can lead to reduced synthesis of proteins including C7orf31, indirectly leading to its decreased activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which plays a role in the MAPK/ERK pathway. As MAPK/ERK signaling often regulates protein expression and function, PD98059 can lead to the functional inhibition of C7orf31 by altering its regulation or expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Since p38 MAPK is involved in stress and inflammatory responses which can regulate protein functions, inhibiting this kinase could lead to a decrease in the functional activity of C7orf31. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which affects transcription factors and cell death pathways. By inhibiting JNK, the inhibitor could prevent the activation of pathways that modulate the stability or activity of C7orf31. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. By preventing protein degradation, it could lead to a negative feedback inhibition of the synthesis of proteins including C7orf31, thereby decreasing its functional activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is another proteasome inhibitor that can block the degradation of ubiquitinated proteins. This can result in the accumulation of regulatory proteins that inhibit the synthesis or function of C7orf31. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases. Similar to LY294002, it can downregulate the PI3K/AKT pathway and potentially inhibit the activity of C7orf31 if it relies on this pathway for its function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. By inhibiting Src kinases, it may influence downstream signaling that regulates the activity or expression of C7orf31. | ||||||